Abstract
Colorectal cancer is one of the most common cancers in the world. Although genomic mutations and single nucleotide polymorphisms have been extensively studied, the epigenomic status in colorectal cancer patient tissues remains elusive. Here, together with genomic and transcriptomic analysis, we use ChIP-Seq to profile active enhancers at the genome wide level in colorectal cancer paired patient tissues (tumor and adjacent tissues from the same patients). In total, we sequence 73 pairs of colorectal cancer tissues and generate 147 H3K27ac ChIP-Seq, 144 RNA-Seq, 147 whole genome sequencing and 86 H3K4me3 ChIP-Seq samples. Our analysis identifies 5590 gain and 1100 lost variant enhancer loci in colorectal cancer, and 334 gain and 121 lost variant super enhancer loci. Multiple key transcription factors in colorectal cancer are predicted with motif analysis and core regulatory circuitry analysis. Further experiments verify the function of the super enhancers governing PHF19 and TBC1D16 in regulating colorectal cancer tumorigenesis, and KLF3 is identified as an oncogenic transcription factor in colorectal cancer. Taken together, our work provides an important epigenomic resource and functional factors for epigenetic studies in colorectal cancer.
Highlights
Colorectal cancer is one of the most common cancers in the world
Many genes related with epigenetic regulation of enhancer activity are frequently mutated in cancer, such as lysine methyltransferase 2 C/D (KMT2C/D, named as MLL3/4), E1A binding protein p300 (EP300), CREB binding protein (CEBBP), lysine demethylase 6 A (KDM6A, named as UTX) and lysine demethylase 5 C (KDM5C)[12,16,17,18,19,20]
We identify thousands of enhancers and multiple transcription factors (TFs) involved in Colorectal cancer (CRC), and a portion of them are experimentally verified, which provides important epigenomic resources and research candidates for future studies in CRC
Summary
Colorectal cancer is one of the most common cancers in the world. genomic mutations and single nucleotide polymorphisms have been extensively studied, the epigenomic status in colorectal cancer patient tissues remains elusive. Pioneer studies hypothesized that gain of enhancer activity is one of the common features for cancers[6,11,12,13], which is supported by some recent studies in patients and animal models[10,14,15]. Genome-wide profiling of active enhancers has been carried out in several types of cancers, such as pancreatic cancer, nasopharyngeal carcinoma, and clear cell renal carcinoma, usually using the approach of H3K27ac ChIPSeq[10,14,26]. A recent study took normal colonic epithelial crypts, CRC cell lines, and four primary patient colorectal tumors, and analyzed the genome-wide difference of active enhancers using H3K27ac ChIP-Seq[33]. Flebbe et al performed H3K27ac in a small number of rectal cancer tissues, but did not analyzed cancer-specific enhancer features[34]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.